Lyell Immunopharma (NASDAQ:LYEL) Releases Earnings Results, Beats Estimates By $0.01 EPS

Lyell Immunopharma (NASDAQ:LYEL) issued its earnings results on Tuesday. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.01, Zacks reports. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%.

Lyell Immunopharma Stock Down 4.0%

LYEL opened at $0.40 on Wednesday. The stock has a market cap of $119.49 million, a PE ratio of -0.51 and a beta of -0.25. The business’s fifty day simple moving average is $0.49 and its 200 day simple moving average is $0.67. Lyell Immunopharma has a 52 week low of $0.39 and a 52 week high of $2.88.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “neutral” rating and set a $1.00 price target on shares of Lyell Immunopharma in a report on Wednesday, April 16th.

Insider Buying and Selling

In related news, CFO Charles W. Newton acquired 200,000 shares of the firm’s stock in a transaction on Monday, March 17th. The stock was acquired at an average cost of $0.56 per share, for a total transaction of $112,000.00. Following the acquisition, the chief financial officer now owns 200,000 shares of the company’s stock, valued at $112,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Lynn Seely bought 175,000 shares of the firm’s stock in a transaction dated Friday, March 14th. The stock was purchased at an average cost of $0.61 per share, with a total value of $106,750.00. Following the transaction, the chief executive officer now directly owns 712,500 shares in the company, valued at approximately $434,625. This represents a 32.56% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 768,640 shares of company stock worth $449,508 in the last 90 days. 25.10% of the stock is owned by company insiders.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.